- Home
- CWK vs XENE Comparison
CWK vs XENE Comparison
Compare CWK & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- XENE
- Stock Information
- Founded
- CWK 1784
- XENE 1996
- Country
- CWK United States
- XENE Canada
- Employees
- CWK N/A
- XENE N/A
- Industry
- CWK Real Estate
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- CWK Finance
- XENE Health Care
- Exchange
- CWK Nasdaq
- XENE Nasdaq
- Market Cap
- CWK 2.7B
- XENE 2.4B
- IPO Year
- CWK 2018
- XENE 2014
- Fundamental
- Price
- CWK $11.93
- XENE $30.50
- Analyst Decision
- CWK Hold
- XENE Strong Buy
- Analyst Count
- CWK 8
- XENE 11
- Target Price
- CWK $13.63
- XENE $54.82
- AVG Volume (30 Days)
- CWK 2.1M
- XENE 806.1K
- Earning Date
- CWK 08-05-2025
- XENE 08-11-2025
- Dividend Yield
- CWK N/A
- XENE N/A
- EPS Growth
- CWK 1337.16
- XENE N/A
- EPS
- CWK 0.69
- XENE N/A
- Revenue
- CWK $9,546,300,000.00
- XENE $7,500,000.00
- Revenue This Year
- CWK $5.56
- XENE N/A
- Revenue Next Year
- CWK $5.66
- XENE $253.71
- P/E Ratio
- CWK $17.57
- XENE N/A
- Revenue Growth
- CWK 1.24
- XENE N/A
- 52 Week Low
- CWK $7.64
- XENE $26.74
- 52 Week High
- CWK $16.11
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- CWK 57.57
- XENE 41.56
- Support Level
- CWK $11.58
- XENE $30.00
- Resistance Level
- CWK $12.68
- XENE $31.87
- Average True Range (ATR)
- CWK 0.34
- XENE 1.01
- MACD
- CWK 0.02
- XENE -0.12
- Stochastic Oscillator
- CWK 56.61
- XENE 17.92
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.